SCHEMBL4787465

SCHEMBL4787465

O=C(O)c1ccc(-c2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.66
CYP1A2 P05177 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP2D6 P10635 2/20 0.62
KDM4E B2RXH2 2/20 0.62
ERBB2 P04626 2/20 0.62
MEN1 O00255 1/20 0.62
NPC1 O15118 1/20 0.62
PRNP P04156 1/20 0.62
MAPT P10636 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
HTT P42858 1/20 0.62
KMT2A Q03164 1/20 0.62
USP2 O75604 1/20 0.62
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62
MAPK1 P28482 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62
RAF1 P04049 4/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301814 0.89 CD38 (0.61) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL17858631 0.89 CD38 (0.61) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL4738594 0.88 EGFR (0.76) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL4787908 0.87 EGFR (0.82) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL4741873 0.86 RAF1 (0.80) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL4741375 0.84 EGFR (0.72) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL17845976 0.83 EGFR (0.64) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL29793375 0.83 EGFR (0.64) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL4738199 0.82 EGFR (0.54) EGFRCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL4737906 0.81 EGFR (0.67) EGFRCYP1A2CYP3A4CYP2D6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 US disclosed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 EGFR 1259/4885CYP1A2 1592/4885CYP3A4 2431/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL EGFR 2964/4885CYP1A2 3697/4885CYP3A4 4330/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG EGFR 3860/4885CYP1A2 610/4885CYP3A4 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.